Alastair Garfield - Jul 8, 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Scientific Officer
Signature
/s/ Hunter Smith, attorney-in-fact for Alastair Garfield
Stock symbol
RYTM
Transactions as of
Jul 8, 2024
Transactions value $
$0
Form type
4
Date filed
7/10/2024, 05:01 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (right to buy) Award $0 +53.3K $0.00 53.3K Jul 8, 2024 Common Stock 53.3K $43.76 Direct F1
transaction RYTM Restricted Stock Units Award $0 +17.8K $0.00 17.8K Jul 8, 2024 Common Stock 17.8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest and become exercisable, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date, as to 6.25% of the total number of shares of common stock subject to the options upon the Reporting Person's completion of each successive three months of service to the Issuer after July 1, 2024, such that the option shall be fully vested and exercisable on July 1, 2028.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3 The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.